Hyderabad, October 16, 2026: Advanced diabetes management technology has brought renewed hope to a 14-year-old boy from the Warangal region who has been living with Type 1 diabetes since early childhood. Treatment at KIMS Cuddles, Secunderabad, has helped improve his glucose control and made it easier for him to participate in everyday activities with greater confidence and independence.

The details were shared by Dr. Kishore Baske, Consultant Paediatric Endocrinologist, Diabetologist and Insulin Pump Specialist, who treated the child, Prahasith.

Since his diagnosis, Prahasith had depended on multiple daily insulin injections and frequent blood glucose monitoring to manage his condition. The need to maintain strict treatment schedules posed challenges in balancing diabetes management with school, sports and social activities. His family was particularly concerned about the possibility of dangerous drops in blood glucose levels during the night, often disrupting their sleep and causing considerable anxiety.

Type 1 diabetes is a chronic autoimmune condition in which the body's immune system destroys the insulin-producing beta cells of the pancreas. As a result, the body produces little or no insulin, making lifelong insulin replacement essential. Regular glucose monitoring, appropriate insulin therapy and ongoing medical supervision are crucial to managing the condition and reducing the risk of long-term complications.

“Children with Type 1 diabetes may require four to six insulin injections a day, along with frequent blood glucose checks. Parents often wake up during the night to ensure that their child's glucose levels have not dropped dangerously low. This places a significant physical and emotional burden on both children and their families,” said Dr. Kishore Baske.

To improve Prahasith's diabetes management, the medical team introduced the Medtronic MiniMed 780G hybrid closed-loop insulin pump system, integrated with the Guardian 4 continuous glucose monitoring (CGM) sensor.

The advanced system continuously tracks glucose levels and automatically adjusts insulin delivery based on the sensor readings and the system's algorithm. This helps maintain glucose levels within the target range for longer periods and reduces the burden of making frequent manual insulin adjustments. However, users still need to monitor their condition, respond to alerts and follow the recommended treatment and device-management protocols.

According to Dr. Baske, Prahasith showed significant improvement in glucose control within a few months of starting pump therapy. The technology also offered greater flexibility in managing his daily routine, allowing him to participate more comfortably in school activities, family gatherings and overnight stays with friends, without being constrained by the same injection schedule he had previously followed.

The benefits extended to his family as well. Continuous glucose monitoring and automated insulin adjustments helped reduce episodes of high and low glucose levels, offering greater reassurance and easing the constant anxiety associated with managing the condition. The extent of improvement, however, depends on individual responses to treatment and consistent use of the system.

Prahasith's family said the change had made a meaningful difference to their everyday lives.

“Earlier, our entire routine revolved around diabetes. We were constantly worried about his food, activities and glucose levels at night. With the insulin pump, he has gained greater independence, and we are also able to lead a more normal family life,” they said.

Dr. Baske emphasised that while advanced insulin pump systems offer significant advantages, proper training and ongoing follow-up are essential for safe and effective use. Families need to understand how the system works, respond to device alerts and replace infusion sets and sensors at the recommended intervals. Regular medical supervision remains important to ensure that treatment settings are appropriate and that any technical or clinical issues are addressed promptly.

“The initial learning process takes time, and families need appropriate guidance to use the technology effectively. However, the potential benefits in glucose management, quality of life and reduction of the daily treatment burden can be substantial,” he said.

He added that advances in diabetes technology were helping children with Type 1 diabetes manage their condition more effectively while participating in activities enjoyed by their peers.

“Our goal is not merely to control blood glucose levels. It is equally important to ensure that children can pursue their ambitions, develop confidence and grow without diabetes becoming a barrier to their lives,” Dr. Baske said.

Prahasith's experience highlights how personalised diabetes care, combined with advanced glucose monitoring and insulin delivery systems, can help ease the everyday challenges of living with Type 1 diabetes and support a better quality of life for children and their families.